Table 4 ART choices in the setting of common co-prescriptions
Patients who purchased medication for specified class of co-prescriptiona | N =1973b n (%) |
|---|---|
Dyslipidemia (any lipid-lowering medication) | 385 (19.5) |
 Purchased protease inhibitorsc | 112 (29.1) |
  darunavir | 71 (63.4) |
  atazanavir | 36 (32.1) |
  r/lopinavir | 9 (8.0) |
  fosamprenavir | 1 (0.8) |
 Purchased efavirenz | 60 (15.6) |
 Purchased elvitegravir | 42 (10.9) |
 Purchased abacavir | 135 (35.1) |
Hypertension or hyperlipidemia or diabetes (at risk for cardiovascular disease) | 574 (29.1) |
Purchased any protease inhibitorc | 155 (27.0) |
  darunavir | 93 (60.0) |
  atazanavir | 50 (32.3) |
  r/lopinavir | 12 (7.7) |
  fosamprenavir | 2 (1.3) |
 Purchased elvitegravir | 74 (12.9) |
 Purchased abacavir | 197 (34.3) |
Hypertension or diabetes (at risk for renal disease) | 413 (20.9) |
 Purchased TDF | 230 (55.7) |
Osteoporosis or low bone mineral density | 27 (1.4) |
 Purchased tenofovir disoproxil fumarate | 13 (48.1) |
Mental illness | 525 (26.6%) |
 Purchased rilpivirine | 79 (15.0) |
 Purchased efavirenz | 38 (7.2) |
Diabetes | 91 (4.6) |
 Purchased protease inhibitorsc | 33 (36.2) |
 Purchased ritonavir-containing regimens | 24 (26.3) |
Proton pump inhibitors | 281 (14.2) |
 Purchased rilpivirine | 15 (5.3) |
 Purchased atazanavir | 11 (3.9) |
Oral contraceptives | 12 (0.6) |
 Purchased protease inhibitorsc | 4 (33.3) |
 Purchased efavirenz | 3 (25.0) |
 Purchased elvitegravir | 1 (8.3) |
Corticosteroids (oral and inhaled except beclomethasone) | 179 (9.1) |
 Purchased protease inhibitorsc | 46 (25.7) |